ArticleInternational journal of molecular sciences2023
In Vivo and In Vitro Characterization of Close Analogs of Compound KA-11, a New Antiseizure Drug Candidate.
Marta Andres-Mach, Mirosław Zagaja, Joanna Szala-Rycaj, Aleksandra Szewczyk, Michał Abram, Marcin Jakubiec, Katarzyna Ciepiela, Katarzyna Socała, Piotr Wlaź, Gniewomir Latacz and 2 more
Open access · goldAbstract read
In one paragraphArticle in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 90% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors at 3 institutions in 1 country.
Marta Andres-MachDepartment of Experimental Pharmacology, Institute of Rural Health, Jaczewskiego 2, 20-950 Lublin, Poland.
Mirosław ZagajaDepartment of Experimental Pharmacology, Institute of Rural Health, Jaczewskiego 2, 20-950 Lublin, Poland.
Joanna Szala-RycajDepartment of Experimental Pharmacology, Institute of Rural Health, Jaczewskiego 2, 20-950 Lublin, Poland.ORCID 0000-0003-2277-1140 Aleksandra SzewczykDepartment of Experimental Pharmacology, Institute of Rural Health, Jaczewskiego 2, 20-950 Lublin, Poland.
Michał AbramDepartment of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, Poland.
Marcin JakubiecDepartment of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, Poland.
Katarzyna CiepielaDepartment of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, Poland.
Katarzyna SocałaDepartment of Animal Physiology and Pharmacology, Institute of Biological Sciences, Faculty of Biology and Biotechnology, Maria Curie-Skłodowska University, Akademicka 19, 20-033 Lublin, Poland.ORCID 0000-0001-7706-2080 Piotr WlaźDepartment of Animal Physiology and Pharmacology, Institute of Biological Sciences, Faculty of Biology and Biotechnology, Maria Curie-Skłodowska University, Akademicka 19, 20-033 Lublin, Poland.ORCID 0000-0002-5389-0241 Gniewomir LataczDepartment of Technology and Biotechnology of Drugs, Jagiellonian University Medical College, Medyczna 9 St., 30-688 Krakow, Poland.ORCID 0000-0001-9247-2598 Nadia KhanDepartment of Technology and Biotechnology of Drugs, Jagiellonian University Medical College, Medyczna 9 St., 30-688 Krakow, Poland.
Krzysztof KaminskiDepartment of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, Poland.ORCID 0000-0003-2103-371X Jagiellonian University · PLInstytut Medycyny Wsi im. Witolda Chodźki · PLMaria Curie-Skłodowska University · PL
Funding
National Science Center UMO-2017/27/B/NZ7/00249
6 · The paper itselfAbstract
Epilepsy is a neurological disorder involving a number of disease syndromes with a complex etiology. A properly matched antiseizure drug (ASD) gives remission in up to 70% of patients. Nevertheless, there is still a group of about 30% of patients suffering from drug-resistant epilepsy. Consequently, the development of new more effective and/or safer ASDs is still an unmet clinical need. Thus, our current studies were focused on the structural optimization/modifications of one of the leading compounds,
Indexed as
Drug Resistant EpilepsyEpilepsyAnimalsAnticonvulsantsDisease Models, AnimalSeizuresAnticonvulsantsacute seizure modelsantiseizure drugsdrug developmentleading compound optimizationphysicochemical descriptors
Identifiers
PMID37176010
PMCPMC10179080
OpenAlexW4372292062
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390